Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Accumulated Expenses (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Accumulated Expenses for 7 consecutive years, with $76.7 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 31.5% to $76.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $76.7 million through Dec 2025, up 31.5% year-over-year, with the annual reading at $76.7 million for FY2025, 31.5% up from the prior year.
  • Accumulated Expenses hit $76.7 million in Q4 2025 for BridgeBio Pharma, up from $56.2 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $76.7 million in Q4 2025 to a low of $300000.0 in Q2 2024.
  • Historically, Accumulated Expenses has averaged $29.4 million across 5 years, with a median of $26.8 million in 2022.
  • Biggest five-year swings in Accumulated Expenses: crashed 99.11% in 2024 and later soared 18618.33% in 2025.
  • Year by year, Accumulated Expenses stood at $37.0 million in 2021, then dropped by 15.62% to $31.3 million in 2022, then surged by 83.55% to $57.4 million in 2023, then rose by 1.67% to $58.3 million in 2024, then skyrocketed by 31.5% to $76.7 million in 2025.
  • Business Quant data shows Accumulated Expenses for BBIO at $76.7 million in Q4 2025, $56.2 million in Q3 2025, and $14.4 million in Q2 2025.